表紙
市場調查報告書

格雷夫氏症:開發中產品分析

Graves Diseases - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 410977
出版日期 內容資訊 英文 49 Pages
訂單完成後即時交付
價格
格雷夫氏症:開發中產品分析 Graves Diseases - Pipeline Review, H2 2019
出版日期: 2019年12月16日內容資訊: 英文 49 Pages
簡介

所謂格雷夫氏症,是由於甲狀腺荷爾蒙的過剩分泌(甲狀腺功能亢進症)而出現的免疫系障礙。症狀有焦慮症,體重的減少,月經週期的變化,勃起障礙,眼球突出,心律不整等。危險因素,為家族病史、年齡、自體免疫疾病、抽煙及妊娠等。用抗甲狀腺藥,β受體阻斷劑及手術等治療。

本報告提供格雷夫氏症的治療藥開發平台的現狀及最新更新的各開發階段比較分析,企業和研究機關最新的新聞和發表開發中的治療藥,治療藥的評估,後期階段及中止的計劃相關資訊等。

簡介

  • 調查範圍

格雷夫氏症 概要

治療藥的開發

  • 開發中產品;概要

企業開發中的治療藥

開發中產品概況

  • 臨床實驗階段的產品
  • 初期階段的產品

企業開發中的產品

開發治療藥的企業

  • Apitope International NV
  • Nova Therapeutics LLC
  • Novartis AG
  • Omeros Corp
  • Rodos BioTarget GmbH

治療藥的評估

  • 單劑產品
  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • ATXGD-59
  • CFZ-533
  • K-170
  • NV-02
  • 格雷夫氏症蛋白質
  • 免疫學、神經學、腫瘤學GPR174標靶藥物

暫停中的計劃

產品開發里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC11805IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Graves Diseases - Pipeline Review, H2 2019, provides an overview of the Graves Diseases (Hormonal Disorders) pipeline landscape.

Graves' disease is an immune system disorder that results in the overproduction of thyroid hormones (hyperthyroidism). Symptoms include anxiety, weight loss, change in menstrual cycles, erectile dysfunction, bulging eyes and irregular heartbeat. Risk factors include family history, age, autoimmune disorders, smoking and pregnancy. Treatment includes anti-thyroid medications, beta blockers and surgery.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Graves Diseases - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Graves Diseases (Hormonal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Graves Diseases (Hormonal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Graves Diseases and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 2 and 2 respectively.

Graves Diseases (Hormonal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Graves Diseases (Hormonal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Graves Diseases (Hormonal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Graves Diseases (Hormonal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Graves Diseases (Hormonal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Graves Diseases (Hormonal Disorders)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Graves Diseases (Hormonal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Graves Diseases (Hormonal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • List of Tables
  • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Graves Diseases - Overview
  • Graves Diseases - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Graves Diseases - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Graves Diseases - Companies Involved in Therapeutics Development
    • advanceCor GmbH
    • Apitope International NV
    • AV7 Ltd
    • GlaxoSmithKline Plc
    • Novartis AG
    • Omeros Corp
    • Rodos BioTarget GmbH
    • Virtici LLC
  • Graves Diseases - Drug Profiles
    • ATXGD-59 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • belimumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • iscalimab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • K-170 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Protein for Graves Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit GPR174 for Immunology, Neurology and Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides for Graves Diseases and Graves Ophthalmopathy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VTCG-90 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Graves Diseases - Dormant Projects
  • Graves Diseases - Product Development Milestones
    • Featured News & Press Releases
      • Jun 20, 2019: Apitope announces publication of data in international peer-reviewed journal thyroid on Graves' disease Therapy
      • Aug 14, 2018: Apitope Announces Publication of Graves' Disease Data in International Peer-Reviewed Journal, Endocrinology
      • Apr 16, 2018: Apitope Announces Positive Results with Novel Treatment for Graves Disease
      • Oct 26, 2016: Apitope Announces Enrolment of First Patient in Phase I Trial of ATX-GD-59 for the Treatment of Graves Disease
      • Jun 19, 2014: Apitope Progresses Graves' Disease Treatment
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Graves Diseases, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Number of Products by Stage and Target, H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Graves Diseases - Pipeline by advanceCor GmbH, H2 2019
  • Graves Diseases - Pipeline by Apitope International NV, H2 2019
  • Graves Diseases - Pipeline by AV7 Ltd, H2 2019
  • Graves Diseases - Pipeline by GlaxoSmithKline Plc, H2 2019
  • Graves Diseases - Pipeline by Novartis AG, H2 2019
  • Graves Diseases - Pipeline by Omeros Corp, H2 2019
  • Graves Diseases - Pipeline by Rodos BioTarget GmbH, H2 2019
  • Graves Diseases - Pipeline by Virtici LLC, H2 2019
  • Graves Diseases - Dormant Projects, H2 2019

List of Figures

  • Number of Products under Development for Graves Diseases, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products by Targets, H2 2019
  • Number of Products by Stage and Targets, H2 2019
  • Number of Products by Mechanism of Actions, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019